New Immune-Boosting drug enters human trials for tough cancers

NCT ID NCT07115043

Summary

This early-stage study aims to find a safe and effective dose of a new drug called AZD6750, which is designed to boost the immune system to fight cancer. It will test the drug alone and combined with other cancer treatments in about 60 adults with advanced or spreading solid tumors, including melanoma, lung, and breast cancers. The main goals are to check for side effects, see how the drug behaves in the body, and get an early look at whether it helps shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Research Site

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Research Site

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Research Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Research Site

    RECRUITING

    East Melbourne, 3002, Australia

  • Research Site

    RECRUITING

    Chūōku, 104-0045, Japan

  • Research Site

    RECRUITING

    Kashiwa, 227-8577, Japan

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 06351, South Korea

Conditions

Explore the condition pages connected to this study.